List Title | APhA DrugInfoLine

Cardiology

SORT BY: Most Recent Most Viewed

September 4, 2018

Lipid-lowering benefits on clinical outcomes relative to baseline LDL value

READ

PREVIEW
A meta-analysis published in JAMA of 34 trials involving more than 270,000 patients showed that more intensive LDL-lowering therapy compared with less-intensive therapy resulted in a...
September 4, 2018

One-dose-fits-all approach to aspirin therapy for primary prevention is not ideal

READ

PREVIEW
The benefits of aspirin therapy appear to be dose dependent, with patients of higher body weight (≥70 kg) requiring higher doses to prevent cardiovascular (CV) events, and similar results observed...
August 21, 2018

Real-world outcomes of direct oral anticoagulants versus warfarin

READ

PREVIEW
Apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) appeared to be the safest direct oral anticoagulant compared with warfarin with respect to major, intracranial, and gastrointestinal bleeding,...
July 9, 2018

Vitamins and mineral supplements have little benefit on CV outcomes

READ

PREVIEW
No significant benefits were observed with use of multivitamins, vitamin D, calcium, or vitamin C on cardiovascular (CV) outcomes or all-cause mortality. Only low- to moderate-quality evidence...
July 2, 2018

Self-monitoring results in better BP control than clinic-based monitoring

READ

PREVIEW
Results of a large, 12-month, open-label, multicenter trial in patients with uncontrolled hypertension showed that self-monitoring (SM) of blood pressure (BP) with or without telemonitoring (TM)...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.